Quick Facts / Company Snapshot
| Metric | Value |
| Company Name | Azenta, Inc. |
| Ticker Symbol | AZTA |
| Stock Exchange | The Nasdaq Stock Market LLC |
| State of Incorporation | Delaware |
| Headquarters | Burlington, Massachusetts |
| CEO | John Marotta |
| CFO | Lawrence Lin |
| Total Revenue (2025) | $593.8 million |
| Net Loss (2025) | $(55.8) million |
| Total Assets (2025) | $2,059.6 million |
| Total Liabilities (2025) | $332.6 million |
| Total Stockholders’ Equity (2025) | $1,727.0 million |
| Operating Loss (2025) | $(26.8) million |
| Total Operating Expenses (2025) | $297.1 million |
| Employee Count | Approximately 3,000 |
| Global Reach | Sales in approximately 95 countries |
| Primary Industry | Life Sciences / Sample Management |
| Fiscal Year End | September 30 |
| Cash and Cash Equivalents (2025) | $279.8 million |
| Marketable Securities (2025) | $262.7 million |
Company Overview
Azenta is a prominent global provider of biological and chemical compound sample exploration and management solutions dedicated to the life sciences industry. The enterprise supports a wide array of clients ranging from pharmaceutical and biotechnology companies to advanced research hospitals and academic institutions. By offering comprehensive capabilities, the organization plays a vital role in advancing the development of therapies aimed at improving human health and curing diseases.
With the rise of personalized medicine and biologics, biological samples have evolved into critical assets for drug and therapy pipelines. Recognizing the necessity for proper management and protection of these assets, the enterprise provides a robust portfolio of products and services that cover the entire lifecycle of a sample.
- Complete Lifecycle Support: The organization assists customers from the initial stages of research and clinical development all the way through to commercialization.
- Diverse Service Portfolio: Offerings include automated ultra-cold storage, sample repository services, and genomic services.
The organization operates with a global footprint, ensuring its solutions reach customers worldwide. By maintaining a strong emphasis on sample integrity, security, and intelligence, the enterprise has established itself as a trusted partner for some of the most cutting-edge institutions and start-ups in the biotechnology space.
Business Segments
The enterprise organizes its operations into two distinct and reportable business segments, allowing it to address specific customer needs across the life sciences spectrum.
- Total 2025 Revenue: $593.8 million.
- Sample Management Solutions: Represents 54.66% of total revenue ($324.6 million).
- Multiomics: Represents 45.34% of total revenue ($269.2 million).
Sample Management Solutions
This segment operates as a unified business unit providing end-to-end sample management products and services. It generated $324.6 million in revenue during the 2025 fiscal year, up from $318.9 million in the previous year. The segment focuses on delivering a high level of sample quality, security, and availability, ensuring a complete “cold chain of custody” for biological assets.
The operational scope of this segment is broad, encompassing both physical infrastructure and expert consultation. It includes Sample Repository Services (SRS) which offer on-site and off-site sample storage, cold chain logistics, and disaster recovery planning. Additionally, the segment provides informatics solutions for laboratory workflow scheduling, temperature monitoring, and clinical trial management.
- Segment Operating Income: The segment achieved an operating income of $20.1 million in 2025, a significant increase from $6.6 million in the prior year.
- Core Product Categories: Includes Automated Stores, Cryogenic Systems, Automated Sample Tubes, Consumables, and Controlled Rate Thawing Devices.
Multiomics
The Multiomics segment functions as a single business unit dedicated to providing genomic and other sample analysis services. In the 2025 fiscal year, this segment contributed $269.2 million to the total revenue, an increase from $254.6 million in the prior year. The segment is designed to advance research and development activities in gene-based healthcare discoveries and therapies.
This segment offers a comprehensive global portfolio that addresses genomic complexity and throughput challenges. The services provided include Next-Generation sequencing (NGS), Sanger sequencing, gene synthesis, and bioinformatics. The business caters to key markets such as cell and gene therapy (CGT), antibody development, and biomarker discovery.
- Segment Operating Loss: The segment recorded an operating loss of $(15.4) million in 2025, compared to a loss of $(11.9) million in the previous year.
- Expert Support: Services are backed by Ph.D.-level project managers who offer consultation, updates, and post-delivery assistance to customers.
History and Evolution
The foundation of the enterprise dates back to 1978, originally establishing itself as a leading automation provider and partner within the global semiconductor manufacturing industry. For decades, the organization honed its expertise in precision automation and cryogenic capabilities.
A major strategic pivot occurred in 2011 when the organization officially entered the life sciences market. By leveraging its deep technological background in automation, the enterprise began developing advanced solutions for automated ultra-cold storage. Over the following years, the business expanded its life sciences footprint significantly through a combination of targeted internal investments and strategic acquisitions.
- Rebranding Initiative: On December 1, 2021, the organization officially changed its corporate name from “Brooks Automation, Inc.” to “Azenta, Inc.”.
- Pure-Play Transition: In February 2022, the enterprise completed the divestiture of its final semiconductor businesses for $2.9 billion in cash, completing its transition into a dedicated, pure-play life sciences company.
- Portfolio Simplification: During the first quarter of the 2025 fiscal year, the business announced its pursuit of selling the B Medical Systems business (a medical refrigeration manufacturer in Luxembourg) to further simplify the portfolio and focus on core segments.
Products and Services
The enterprise classifies its revenue generation into two primary streams: Products and Services.
- Total Services Revenue (2025): $420.6 million (70.83% of total revenue).
- Total Products Revenue (2025): $173.2 million (29.17% of total revenue).
Services
The Services category is the dominant revenue driver for the organization, encompassing a wide range of analytical and logistical offerings. This includes biological sample services such as DNA sequencing, gene synthesis, molecular biology, and bioinformatics. It also covers sample acquisition, biological sample storage, repairs, upgrades, and diagnostic support.
The genomic services are designed for rapid turnaround, with the simplest genomics and synthesis requests often completed in less than 24 hours, while more complex projects are finalized within weeks. Customers benefit from highly integrated workflows that support complex research in biologics and personalized medicine.
- Sample Repository Services (SRS): Features comprehensive on-site and off-site sample storage, cold chain logistics, and bio-processing solutions.
- Consultation Expertise: Provides specialized consultation services throughout the experimental design and implementation phases.
Products
The Products category includes the sale of physical infrastructure and software necessary for robust sample management. Offerings range from automated cold sample management systems to consumables, instruments, spare parts, and proprietary software.
Automated stores are a key highlight, featuring stand-alone systems capable of housing over 20 million samples in temperatures ranging from ambient down to -80°C. The portfolio also features cryogenic systems that utilize high-efficiency liquid nitrogen vapor for long-term preservation, maintaining sample integrity across the entire cold chain.
- Consumables and Instruments: A complete range of racks, tubes, caps, and plates, complemented by instruments for labeling, capping, and sealing.
- Controlled Rate Thawing Devices: Specialized products for the automated thawing of plasma, blood, and stem cells, crucial for cell and gene therapy applications.
Brand Portfolio
While the enterprise operates globally under its primary corporate identity, it manages distinct business lines and acquired entities that contribute to its overarching market presence.
- Primary Corporate Brand: Representing the entire suite of sample management and multiomics solutions.
- B Medical Systems: A manufacturer and global distributor of medical refrigeration devices based in Luxembourg.
- GENEWIZ: The organization operates multiple entities worldwide bearing the GENEWIZ name, serving as a cornerstone for its genomic and multiomics services footprint.
Note: In the 2025 fiscal year, the B Medical Systems business was classified as held for sale and treated as a discontinued operation, representing a strategic shift to focus purely on the core Sample Management Solutions and Multiomics segments.
Geographical Presence
The enterprise maintains a vast international footprint, ensuring close proximity to major pharmaceutical hubs, research hospitals, and academic institutions worldwide. Revenue is highly diversified, with a significant portion generated outside of North America.
- North America Revenue Contribution: Approximately 61% of total revenue in 2025 (Calculated from 39% derived outside North America).
- International Revenue Contribution: Approximately 39% of total revenue in 2025.
United States Facilities
The United States serves as the primary operational base and headquarters for the organization. The corporate headquarters is situated in Burlington, Massachusetts, covering approximately 88,400 square feet. Other major facilities include an expansive sample storage and sales support center in Indianapolis, Indiana (116,700 square feet), and a combined manufacturing, R&D, and sales facility in Plainfield, Indiana (67,900 square feet).
Additional key U.S. locations include a laboratory and office space in South Plainfield, New Jersey (73,300 square feet), and a manufacturing and R&D site in Springfield, Missouri (50,100 square feet). These facilities are instrumental in supporting both the Sample Management Solutions and Multiomics segments.
- Billerica, Massachusetts: Houses sample storage, R&D, and office spaces covering 39,900 square feet.
- Domestic Network: The organization operates a total of seven laboratories providing genomic services within the United States.
International Facilities
The enterprise has established a strong presence in Europe and Asia to cater to local market demands and optimize global supply chains. A major laboratory and office facility is located in Suzhou, China, functioning as a massive 240,000 square foot hub for the Multiomics segment.
In Europe, the organization operates a manufacturing and office facility in Manchester, United Kingdom (44,700 square feet), which supports the Sample Management Solutions segment. The company maintains a network of genomic laboratories internationally, including three in China, two in the United Kingdom, one in Japan, and one in Germany.
- Global Sample Management: Facilities providing sample storage and transportation services are located in Griesheim (Germany), Montreal (Canada), Singapore, and Beijing (China).
- Asian Market Focus: The organization anticipates that international sales, particularly in Asia and China, will continue to represent a significant portion of future revenue.
Profit and Loss
The organization’s financial performance reflects its ongoing investments in research, development, and operational restructuring. The data below outlines the consolidated statements of operations for the most recent fiscal years.
| Metric | 2025 | 2024 | 2023 |
| Total Revenue | $593,821,000 | $573,448,000 | $551,486,000 |
| Total Cost of Revenue | $323,541,000 | $318,826,000 | $312,276,000 |
| Gross Profit | $270,280,000 | $254,622,000 | $239,210,000 |
| Research and Development | $30,390,000 | $31,524,000 | $32,141,000 |
| Selling, General and Administrative | $261,563,000 | $262,958,000 | $263,738,000 |
| Restructuring Charges | $5,171,000 | $6,766,000 | $4,577,000 |
| Impairment of Goodwill and Intangibles | $0 | $4,658,000 | $0 |
| Total Operating Expenses | $297,124,000 | $305,906,000 | $300,456,000 |
| Operating Loss | $(26,844,000) | $(51,284,000) | $(61,246,000) |
| Interest Income, Net | $18,779,000 | $32,891,000 | $43,541,000 |
| Income Tax (Benefit) Expense | $(31,601,000) | $5,241,000 | $(11,965,000) |
| Income (Loss) from Continuing Operations | $24,458,000 | $(24,366,000) | $(8,040,000) |
| Loss from Discontinued Operations (Net of Tax) | $(80,221,000) | $(140,531,000) | $(6,596,000) |
| Net Loss | $(55,763,000) | $(164,897,000) | $(14,636,000) |
Balance Sheet
The balance sheet highlights a strong liquidity position, supported by significant cash reserves and marketable securities.
| Asset / Liability Category | September 30, 2025 | September 30, 2024 |
| Cash and Cash Equivalents | $279,783,000 | $280,030,000 |
| Short-term Marketable Securities | $61,137,000 | $151,162,000 |
| Accounts Receivable (Net) | $142,181,000 | $154,172,000 |
| Inventories | $74,956,000 | $71,320,000 |
| Current Assets Held for Sale | $73,535,000 | $99,052,000 |
| Total Current Assets | $708,339,000 | $833,031,000 |
| Property, Plant and Equipment (Net) | $153,954,000 | $155,622,000 |
| Goodwill | $702,395,000 | $691,409,000 |
| Intangible Assets (Net) | $101,814,000 | $125,042,000 |
| Total Assets | $2,059,582,000 | $2,100,265,000 |
| Accounts Payable | $37,722,000 | $33,344,000 |
| Deferred Revenue | $31,569,000 | $30,493,000 |
| Total Current Liabilities | $237,674,000 | $206,089,000 |
| Long-term Operating Lease Liabilities | $51,244,000 | $56,677,000 |
| Total Liabilities | $332,596,000 | $332,418,000 |
| Retained Earnings | $1,419,956,000 | $1,475,719,000 |
| Total Stockholders’ Equity | $1,726,986,000 | $1,767,847,000 |
Cash Flow
The enterprise’s cash flow statement demonstrates dynamic shifts in operating, investing, and financing activities over the last three fiscal years.
| Cash Flow Category | 2025 | 2024 | 2023 |
| Net Cash Provided by Operating Activities | $72,217,000 | $49,699,000 | $105,483,000 |
| Net Cash Provided by (Used in) Investing Activities | $96,083,000 | $205,191,000 | $(118,655,000) |
| Net Cash Used in Financing Activities | $(164,888,000) | $(239,944,000) | $(851,756,000) |
| Effect of Exchange Rate Changes on Cash | $(2,210,000) | $(15,313,000) | $(4,037,000) |
| Net Increase (Decrease) in Cash and Equivalents | $1,202,000 | $(367,000) | $(868,965,000) |
| Cash, Equivalents, and Restricted Cash (End of Year) | $283,506,000 | $282,304,000 | $282,671,000 |
Board of Directors and Leadership Team
The strategic direction and operational execution of the enterprise are guided by a dedicated Board of Directors and an experienced executive leadership team.
- John Marotta: Serves as the President, Chief Executive Officer, and Director of the organization. He acts as the Principal Executive Officer, leading the company’s global strategic initiatives.
- Lawrence Lin: Holds the position of Executive Vice President and Chief Financial Officer. He acts as the Principal Financial and Accounting Officer, overseeing the financial health and reporting of the enterprise.
- Frank E. Casal: Serves as a Director on the Board.
- Robyn C. Davis: Serves as a Director on the Board.
- Dipal Doshi: Serves as a Director on the Board.
- Quentin Koffey: Serves as a Director on the Board.
- Alan J. Malus: Serves as a Director on the Board.
The board is highly involved in corporate governance, overseeing compliance with federal and state laws, SEC requirements, and Nasdaq regulations.
Subsidiaries, Associates, Joint Ventures
The enterprise operates a vast network of global subsidiaries to facilitate its international operations across the life sciences and multiomics sectors. These subsidiaries are wholly integrated into the company’s consolidated financial structure.
| Subsidiary Name | Country of Jurisdiction | Business Segment / Activity |
| Azenta Beijing Technologies Limited | China | Sample Management / Multiomics |
| Azenta (Guangzhou) Life Science Co., Ltd. | China | Sample Management / Multiomics |
| Azenta Germany GmbH | Germany | Sample Management / Multiomics |
| Azenta Japan Corp. | Japan | Sample Management / Multiomics |
| Azenta Life Sciences Canada, Inc. | Canada | Sample Management / Multiomics |
| Azenta Luxembourg SARL | Luxembourg | Sample Management / Multiomics |
| Azenta Switzerland AG | Switzerland | Sample Management / Multiomics |
| Azenta Singapore Pte Ltd. | Singapore | Sample Management / Multiomics |
| Azenta UK Ltd | United Kingdom | Sample Management / Multiomics |
| Azenta US, Inc. | United States | Sample Management / Multiomics |
| GENEWIZ Group | USA | Multiomics (Genomic Services) |
| GENEWIZ Inc. | USA | Multiomics (Genomic Services) |
| GENEWIZ France Ltd. | France | Multiomics (Genomic Services) |
| GENEWIZ (Suzhou), Ltd. | China | Multiomics (Genomic Services) |
| Barkey Corporation | USA | Sample Management (Thawing Devices) |
| Barkey GmbH & Co. KG | Germany | Sample Management (Thawing Devices) |
Note: The B Medical Systems entities (e.g., B Medical Systems India Private Limited, B Medical Systems North America LLC, B Medical Systems SARL) are classified as held for sale and discontinued operations.
Other Investments (Including Minority / Portfolio Holdings)
To optimize its capital resources and ensure liquidity, the enterprise actively manages a portfolio of short-term and long-term marketable securities. These investments are highly rated and carefully monitored for market risks.
| Investment Category | Fair Value (Sept 30, 2025) | Fair Value (Sept 30, 2024) |
| U.S. Treasury and U.S. Agency Securities | $245.8 million | $185.0 million |
| Bank Certificates of Deposits | $1.6 million | $6.2 million |
| Corporate Securities | $4.2 million | $9.3 million |
| Municipal Securities | $11.1 million | $0 |
| Total Marketable Securities | $262.7 million | $200.6 million |
- Nature of Investment: These are passive, financial investments held as available-for-sale securities, designed to preserve capital while generating interest income.
- Classification: Classified primarily within Level 1 of the fair value hierarchy (active market quotes), with some certificates of deposit and corporate securities classified as Level 2 (observable market inputs).
Physical Properties (Offices, Plants, Factories, etc.)
The organization manages a strategic portfolio of owned and leased properties that house its critical manufacturing, research and development, laboratory, and administrative functions.
| Location | Primary Functions | Segment | Approx. Square Footage | Ownership Status / Lease Expiration |
| Suzhou, China | Laboratory & Office | Multiomics | 240,000 | Owned |
| Indianapolis, Indiana | Sample Storage, Sales & Support | Sample Management Solutions | 116,700 | Leased (Expires Sept 2043) |
| South Plainfield, New Jersey | Laboratory & Office | Multiomics | 73,300 | Leased (Expires Jan 2030) |
| Plainfield, Indiana | Manufacturing, R&D, Sales & Support | Sample Management Solutions | 67,900 | Leased (Expires Aug 2042) |
| Springfield, Missouri | Manufacturing, R&D, Sales & Support | Sample Management Solutions | 50,100 | Leased (Expires Dec 2028) |
| Manchester, United Kingdom | Manufacturing & Office | Sample Management Solutions | 44,700 | Leased (Expires Dec 2029) |
| Billerica, Massachusetts | Sample Storage, R&D, Office | Sample Management Solutions | 39,900 | Leased (Expires Oct 2033) |
| Burlington, Massachusetts | Corporate Headquarters | Corporate | 88,400 | Leased (Expires Jan 2033) |
Founders
The enterprise traces its roots to its original incorporation in 1978, initially entering the market as an automation provider for the global semiconductor manufacturing industry. Over the decades, it evolved significantly, shedding its legacy industrial roots to become a pure-play life sciences leader.
Parent
The enterprise functions as an independent, publicly-traded corporation (Azenta, Inc.) listed on the Nasdaq Stock Market. It does not operate under a parent holding company.
Investments and Capital Expenditure Plans
The organization consistently invests in its physical and technological infrastructure to maintain its competitive edge and support continuous product innovation.
- Research and Development (R&D): The enterprise views R&D as a critical engine for growth. In the 2025 fiscal year, R&D expenses reached $30.4 million. These funds are directed toward developing new automated biological sample storage solutions, advancing genomic services protocols, and enhancing data management software.
- Strategic Divestitures: In a major move to optimize capital allocation, the company initiated the sale of its B Medical Systems business in 2025, enabling management to focus financial resources entirely on the core SMS and Multiomics segments.
- Capital Sourcing: The business believes its current cash and cash equivalents of $283.5 million (including restricted cash), along with $262.7 million in marketable securities, are more than sufficient to fund operating expenses and capital expenditure requirements for the foreseeable future.
Shareholding Pattern
The enterprise maintains a transparent equity structure and has aggressively returned capital to shareholders through comprehensive stock repurchase programs.
- Total Shares Outstanding: As of December 1, 2025, the company had 45,989,285 shares of Common Stock outstanding.
- Share Repurchase Program: Under a $1.5 billion repurchase authorization approved in 2022, the company executed massive buybacks. By September 30, 2024, the enterprise had repurchased and retired a total of 30.0 million shares of common stock, fully exhausting the $1.5 billion authorization.
- Non-Affiliate Holdings: As of March 31, 2025, the aggregate market value of the company’s common stock held by non-affiliates was approximately $1.0 billion.
- Dividend Policy: Following the sale of its semiconductor automation business in early 2022, the enterprise ceased paying dividends and currently has no plans to issue dividends, choosing instead to reinvest capital into the business.
Future Strategy
The organization’s forward-looking strategy is deeply rooted in capitalizing on the explosive growth within the life sciences market, particularly concerning biologics, personalized medicine, and cell and gene therapies (CGT).
- Focus on Core Segments: The ongoing divestiture of the B Medical Systems business exemplifies the strategy to simplify the portfolio and double down on driving revenue growth and profitability strictly within the Sample Management Solutions and Multiomics sectors.
- Technological Expansion: The enterprise intends to continuously introduce new products and enhance existing automation software to streamline “sample-to-data” workflows for researchers.
- Strategic Acquisitions: The organization relies on a robust acquisition and integration approach to accelerate internal development and drastically reduce time-to-market for new life sciences solutions.
- Global Penetration: The business expects international sales, specifically in Asia and China, to remain a vital part of its revenue trajectory, despite plans to shift certain operational processes outside of China to mitigate geopolitical risks.
Key Strengths
The enterprise leverages a unique combination of technological prowess and operational scale to maintain a formidable market position.
- End-to-End Capabilities: The organization offers a complete suite of services that cover the entire lifecycle of a sample, providing unbroken “cold chain of custody” capabilities that pharmaceutical companies highly value.
- Massive Scale: The automated stores are capable of managing over 20 million samples per standalone unit at ultra-cold temperatures, offering the industry’s highest throughput for sample retrieval.
- Global Infrastructure: With 14 genomic laboratories worldwide (including locations in the US, China, UK, Japan, and Germany) and sample storage facilities across major continents, the enterprise can support global clinical trials with unmatched logistical efficiency.
- Financial Fortitude: A fortress balance sheet featuring nearly $540 million in cash, cash equivalents, and marketable securities ensures the company can weather macroeconomic storms and pursue aggressive M&A opportunities.
Key Challenges and Risks
Despite its strong market position, the organization navigates a complex landscape of operational, regulatory, and macroeconomic risks.
- Geopolitical and Supply Chain Friction: The global nature of the business exposes it to trade disputes, tariffs, and supply chain disruptions. Geopolitical tensions, particularly the U.S.-China dynamic, pose risks of export controls or restricted access to raw materials, which could delay production and inflate costs .
- Regulatory Hurdles: The life sciences industry is intensely regulated. Changes in environmental regulations, global climate change mandates, or ethical restrictions surrounding genetic engineering and gene synthesis could limit market opportunities and increase compliance costs .
- Cybersecurity Threats: The business relies heavily on critical information systems to protect sensitive customer data and genomic information. A failure, breach, or ransomware attack could result in severe operational disruptions, financial exposure, and permanent reputational damage.
- Customer Concentration and Contracts: Sales are frequently driven by individual purchase orders rather than long-term binding contracts, meaning customers can abruptly shift to competitors, leading to unpredictable revenue fluctuations.
- Intellectual Property Vulnerability: The enterprise’s competitive edge relies heavily on patents and trade secrets. Failure to protect these assets, or claims of third-party infringement, could result in the loss of proprietary technology or costly litigation .
Conclusion and Strategic Outlook
Azenta has successfully executed one of the most ambitious corporate transformations in recent history, completely divesting its legacy semiconductor operations to emerge as a powerhouse in the life sciences sector. By providing the critical infrastructure necessary for biological sample management and genomic sequencing, the enterprise sits at the very heart of the modern drug discovery ecosystem.
Financially, the company is highly capitalized, allowing it to navigate short-term macroeconomic headwinds while continuing to invest in next-generation automated storage and multiomics capabilities. The strategic decision to divest the B Medical Systems unit underscores a disciplined management approach focused entirely on maximizing margins and growth in core areas. As personalized medicine, biologics, and cell and gene therapies continue to expand globally, Azenta is uniquely positioned to serve as the indispensable “picks and shovels” provider for the world’s leading research institutions and pharmaceutical giants.
FAQ
What is Azenta’s primary business focus?
The enterprise is a global provider of biological and chemical compound sample management solutions, as well as multiomics services like gene sequencing and synthesis, catering exclusively to the life sciences industry.
When did the company change its name to Azenta?
The organization changed its corporate name from “Brooks Automation, Inc.” to “Azenta, Inc.” on December 1, 2021, to reflect its dedicated focus on life sciences.
What are the two main business segments of the company?
The business operates through two primary segments: Sample Management Solutions (providing automated storage, consumables, and repository services) and Multiomics (providing genomic sequencing and synthesis services).
Does the company pay a dividend to shareholders?
No, since completing the sale of its semiconductor automation business in early 2022, the enterprise has not paid any dividends and currently has no plans to do so.
How many people does the organization employ?
As of September 30, 2025, the enterprise employs approximately 3,000 full-time, part-time, and contingent workers globally.
Where is the corporate headquarters located?
The global corporate headquarters is located in Burlington, Massachusetts, USA.
What is the “B Medical Systems” business?
It is a manufacturer and distributor of medical refrigeration devices located in Luxembourg. In 2025, the company classified this business as held for sale to focus solely on its core sample management and multiomics operations.
Official Site: https://www.azenta.com/
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
